MM-302: Phase II started

Merrimack began the open-label, international Phase II HERMIONE trial to compare MM-302 plus Herceptin trastuzumab vs. physician’s choice of chemotherapy plus Herceptin in about 250 anthracycline-naive patients with HER2-positive, locally advanced or metastatic breast cancer. Patients must have received prior treatment with Herceptin in any setting and Perjeta pertuzumab and Kadcyla ado-trastuzumab emtansine ( T-DM1) in the locally advanced or metastatic setting. Merrimack said HERMIONE will potentially support a regulatory application for accelerated approval. ...